CEO Jeff Cleland, PhD, reports the company is moving ahead with trial design for a single ascending-dose study of its candidate GB-102 for intravitreal injection in retinal disease. The trial would involve patients already on anti-VEGF therapy and inform dosing and regimen for a larger Phase II trial later on. GB-102 is a clinical-stage depot formulation of sunitinib malate encapsulated within bioabsorbable microparticles.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.